Relmada Therapeutics, Inc.

NasdaqCM:RLMD Stock Report

Market Cap: US$463.5m

Relmada Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqCM:RLMD Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
15 Dec 25BuyUS$48,060Maged ShenoudaIndividual11,665US$4.12
15 Dec 25BuyUS$113,300Sergio TraversaIndividual27,500US$4.12
05 Nov 25BuyUS$1,100,000Maged ShenoudaIndividual500,000US$2.20
05 Nov 25BuyUS$599,500Sergio TraversaIndividual272,500US$2.20
05 Nov 25BuyUS$299,200Charles EnceIndividual136,000US$2.20
05 Nov 25BuyUS$198,000Paul KellyIndividual90,000US$2.20
28 Aug 25BuyUS$178,095Sergio TraversaIndividual265,976US$0.74
20 May 25BuyUS$174,713Sergio TraversaIndividual350,000US$0.56
20 May 25BuyUS$97,208Maged ShenoudaIndividual200,000US$0.52
16 May 25BuyUS$103,330Charles EnceIndividual228,961US$0.45
16 May 25BuyUS$86,060Paul KellyIndividual200,000US$0.43

Insider Trading Volume

Insider Buying: RLMD insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of RLMD?
Owner TypeNumber of SharesOwnership Percentage
Private Companies3,017,4204.11%
Individual Insiders4,906,1566.69%
General Public14,280,19119.5%
Hedge Funds15,056,18120.5%
Institutions36,073,67449.2%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 143%.

Top Shareholders

Top 25 shareholders own 72.82% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.1%
Janus Henderson Group plc
7,439,415US$47.0m2.33%0.02%
9.14%
Squadron Capital Management Llc
6,700,000US$42.3m103%18.25%
5.82%
Adage Capital Management, L.P.
4,270,000US$27.0m0%0.04%
5.57%
Spruce Street Capital LP
4,086,181US$25.8m0%7.81%
4.35%
Marshall Wace LLP
3,189,662US$20.2m1,070%0.02%
4.18%
Ikarian Capital, LLC
3,068,359US$19.4m-13.4%2.69%
4.11%
Trigone Pharma Ltd.
3,017,420US$19.1m0%no data
3.56%
OrbiMed Advisors LLC
2,610,600US$16.5m0%0.25%
2.62%
Columbia Management Investment Advisers, LLC
1,920,099US$12.1m0%no data
2.59%
Kevin Kotler
1,899,930US$12.0m0%no data
2.56%
Driehaus Capital Management LLC
1,880,006US$11.9m154%0.06%
2.28%
Millennium Management LLC
1,673,017US$10.6m0%0.01%
2.16%
Braidwell LP
1,582,257US$10.0m0%0.39%
1.77%
Sergio Traversa
1,300,000US$8.2m30%no data
1.73%
BlackRock, Inc.
1,267,503US$8.0m150%no data
1.64%
The Vanguard Group, Inc.
1,203,307US$7.6m187%no data
1.27%
Opaleye Management Inc.
935,000US$5.9m0%0.8%
1.17%
Geode Capital Management, LLC
854,932US$5.4m189%no data
1.14%
Boothbay Fund Management, LLC
835,300US$5.3m20.5%0.14%
1.09%
Maged Shenouda
800,000US$5.1m177%no data
0.98%
Corient Private Wealth LLC
719,582US$4.5m248%0.01%
0.78%
Two Sigma Investments, LP
572,835US$3.6m230%0.01%
0.75%
Balyasny Asset Management L.P.
547,854US$3.5m0%0.01%
0.72%
Acadian Asset Management LLC
526,718US$3.3m-9.58%no data
0.68%
Paul Kelly
502,295US$3.2m21.8%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/03/12 22:02
End of Day Share Price 2026/03/12 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Relmada Therapeutics, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Maxim JacobsEdison Investment Research
Farzin HaqueJefferies LLC
Andrew TsaiJefferies LLC